Table 1.
Baseline Characteristics of the Trial Population.
| Characteristics | SABR, No. (%) | I-SABR, No. (%) |
|---|---|---|
| Sex | ||
| Female | 41 (55) | 46 (70) |
| Male | 34 (45) | 20 (30) |
| Race | ||
| White | 64 (85) | 62 (94) |
| Non-White | 11 (15) | 4 (6) |
| Age, years | ||
| Median (IQR) | 72 (66–78) | 72 (66–75) |
| Smoking Status | ||
| Never | 7 (9) | 7 (11) |
| Current/Previous | 68 (91) | 59 (89) |
| ECOG Performance Status Score | ||
| 0–1 | 68 (91) | 62 (94) |
| 2 | 7 (9) | 4 (6) |
| Tumor Histology | ||
| Non-squamous carcinoma | 61 (81) | 55 (83) |
| Squamous cell carcinoma | 14 (19) | 11 (17) |
| Tumor Size, cm | ||
| Median (IQR) | 1.7 (1.3–2.2) | 2.0 (1.4–2.6) |
| ≤2 cm | 51 (68) | 35 (53) |
| 2–3 cm | 16 (21) | 22 (33) |
| 3–5 cm | 8 (11) | 9 (14) |
| Volume of GTV, cc | ||
| Median (IQR) | 4.2 (2.4–9.1) | 6.4 (2.5–15.1) |
| Lung Cancer History | ||
| Newly diagnosed | 63 (84) | 50 (76) |
| Recurrent | 12 (16) | 16 (24) |
| Single lesion | 74 (99) | 62 (94) |
| Two lesions | 1 (1) | 4 (6) |
| SABR Regimen | ||
| 50 Gy in 4 fractions | 63 (84) | 59 (89) |
| 70 Gy in 10 fractions | 12 (16) | 7 (11) |
| No of Nivolumab Cycles, | N/A | |
| median (IQR) | 4 (4–4) | |
| ≤ 2 | 11 (17) | |
| >2 | 55 (83) | |
| PD-L1 status | ||
| <1% | 34 (45) | 27 (41) |
| ≥1% | 16 (21) | 15 (23) |
| Unknown | 25 (33) | 24 (36) |
| EGFR status | ||
| Wild-type | 22 (29) | 25 (38) |
| Mutated | 3 (4) | 1 (2) |
| Unknown | 50 (67) | 40 (61) |
| Underwent EBUS | ||
| Yes | 50 (65) | 43 (65) |
| No | 25 (35) | 23 (35) |
| Received Brain MRI | ||
| Yes | 40 (53) | 34 (52) |
| No | 35 (47) | 32 (48) |
Abbreviations: SABR, stereotactic ablative radiotherapy; I-SABR, immunotherapy + stereotactic ablative radiotherapy; IQR, interquartile range; ECOG, Eastern Cooperative Oncology Group; GTV, gross tumor volume; Gy, Gray; N/A, not applicable; PD-L1, programmed cell death ligand-1; EGFR, epidermal growth factor receptor